| Bioactivity | Alunacedase alfa (HrsACE2; GSK 2586881) is a human recombinant soluble angiotensin-converting enzyme-2 (hrsACE2). Alunacedase alfa is a genetically modified soluble form of ACE2, it decreases cell entry of SARS-CoV-2 competing for membrane-bound ACE2. Alunacedase alfa has the potential for the research of SARS-CoV-2[1][2]. |
| Invitro | Alunacedase alfa binds to the spike glycoprotein of SARS-CoV-2 at an affinity calculated to be approximately 1·2 nM[2]. |
| Name | Alunacedase alfa |
| CAS | 2416824-55-8 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Abd El-Aziz TM, et al. Human recombinant soluble ACE2 (hrsACE2) shows promise for treating severe COVID-19. Signal Transduct Target Ther. 2020 Nov 3;5(1):258. [2]. Zoufaly A, et al. Human recombinant soluble ACE2 in severe COVID-19. Lancet Respir Med. 2020 Nov;8(11):1154-1158. |